All articles
Diagnostikare, end-to-end digital health services for enterprises
See how Infermedica API is used in Diagnostikare, a Mexican digital platform offering health services for patients and enterprises.
Areas to check before launching a healthcare app on Infermedica API
Everything you should know and double-check before launching the new healthcare application based on Infermedica API.
The multi-step clinical validation process at Infermedica
Validation is a vital part of creating medical content at Infermedica. See our testing methods and ways to improve the medical knowledge base.
Building a quality digital medical knowledge base
Our medical information base lies at the very heart of Infermedica solutions. We present 6 things that are the key to its quality and accuracy.
Sana Kliniken AG implements symptom checker
We formed a partnership with Sana Kliniken, one of the largest German healthcare providers.
Infermedica closes Series A funding with $10.25M
We are entering the next stage of growth. See how the new funds will accelerate the development of our AI-based solutions for healthcare.
Microsoft partners up with Infermedica
Infermedica provides technology to the Microsoft Healthcare Bot Service, empowering others to use AI-based virtual assistants at scale.
COVID-19 Risk Assessment ChatBot is live
Infermedica and LiveChat joined forces to create a chatbot to help in the fight against COVID-19.
COVID-19 Risk Assessment tool is here
As the pandemic emerged, our team worked non-stop and released a free COVID-19 risk evaluation tool.
COVID-19 and Infermedica
COVID-19 is more than just a hot topic. Helping patients quickly assess their risk of coronavirus is how we are fighting this global crisis.
Why is 2020 a turning point for healthcare?
What changes are on the horizon at the beginning of 2020? Eight remarkable transformative forces are expected for the upcoming months.
Infermedica 2019: Year in Review
2019 was a breakthrough. We've managed to grow our team, gain new clients, improve the product, and raise additional funding.